Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2001 Sep-Oct;7(5):820–827. doi: 10.3201/eid0705.010508

Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery.

G Zanetti 1, S J Goldie 1, R Platt 1
PMCID: PMC2631870  PMID: 11747694

Abstract

Routine us of vancomycin for perioperative prophylaxis is discouraged, principally to minimize microbial resistance to it. However, outcomes and costs of this recommendation have not been assessed. We used decision-analytic models to compare clinical results and cost-effectiveness of no prophylaxis, cefazolin, and vancomycin, in coronary artery bypass graft surgery. In the base case, vancomycin resulted in 7% fewer surgical site infections and 1% lower all-cause mortality and saved $117 per procedure, compared with cefazolin. Cefazolin, in turn, resulted in substantially fewer infections and deaths and lower costs than no prophylaxis. We conclude that perioperative antibiotic prophylaxis with vancomycin is usually more effective and less expensive than cefazolin. Data on vancomycin's impact on resistance are needed to quantify the trade-off between individual patients' improved clinical outcomes and lower costs and the future long-term consequences to society.

Full Text

The Full Text of this article is available as a PDF (75.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bencini P. L., Galimberti M., Signorini M., Crosti C. Antibiotic prophylaxis of wound infections in skin surgery. Arch Dermatol. 1991 Sep;127(9):1357–1360. [PubMed] [Google Scholar]
  2. Bold R. J., Mansfield P. F., Berger D. H., Pollock R. E., Singletary S. E., Ames F. C., Balch C. M., Hohn D. C., Ross M. I. Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg. 1998 Sep;176(3):239–243. doi: 10.1016/s0002-9610(98)00154-8. [DOI] [PubMed] [Google Scholar]
  3. Coast J., Smith R. D., Millar M. R. An economic perspective on policy to reduce antimicrobial resistance. Soc Sci Med. 1998 Jan;46(1):29–38. doi: 10.1016/s0277-9536(97)00132-9. [DOI] [PubMed] [Google Scholar]
  4. Dellinger E. P., Gross P. A., Barrett T. L., Krause P. J., Martone W. J., McGowan J. E., Jr, Sweet R. L., Wenzel R. P. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis. 1994 Mar;18(3):422–427. doi: 10.1093/clinids/18.3.422. [DOI] [PubMed] [Google Scholar]
  5. Fong I. W., Baker C. B., McKee D. C. The value of prophylactic antibiotics in aorat-coronary bypass operations: a double-blind randomized trial. J Thorac Cardiovasc Surg. 1979 Dec;78(6):908–913. [PubMed] [Google Scholar]
  6. Fryback D. G., Dasbach E. J., Klein R., Klein B. E., Dorn N., Peterson K., Martin P. A. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993 Apr-Jun;13(2):89–102. doi: 10.1177/0272989X9301300202. [DOI] [PubMed] [Google Scholar]
  7. Garrelts J. C., Horst W. D., Silkey B., Gagnon S. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy. 1994 Jul-Aug;14(4):438–445. [PubMed] [Google Scholar]
  8. Ghali W. A., Ash A. S., Hall R. E., Moskowitz M. A. Statewide quality improvement initiatives and mortality after cardiac surgery. JAMA. 1997 Feb 5;277(5):379–382. [PubMed] [Google Scholar]
  9. Hall R. E., Ash A. S., Ghali W. A., Moskowitz M. A. Hospital cost of complications associated with coronary artery bypass graft surgery. Am J Cardiol. 1997 Jun 15;79(12):1680–1682. doi: 10.1016/s0002-9149(97)00223-3. [DOI] [PubMed] [Google Scholar]
  10. Hlatky M. A., Rogers W. J., Johnstone I., Boothroyd D., Brooks M. M., Pitt B., Reeder G., Ryan T., Smith H., Whitlow P. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1997 Jan 9;336(2):92–99. doi: 10.1056/NEJM199701093360203. [DOI] [PubMed] [Google Scholar]
  11. Jarvis W. R. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis. 1998 May;26(5):1200–1203. doi: 10.1086/520284. [DOI] [PubMed] [Google Scholar]
  12. Kaiser A. B. Antimicrobial prophylaxis in surgery. N Engl J Med. 1986 Oct 30;315(18):1129–1138. doi: 10.1056/NEJM198610303151805. [DOI] [PubMed] [Google Scholar]
  13. Kaiser A. B., Clayson K. R., Mulherin J. L., Jr, Roach A. C., Allen T. R., Edwards W. H., Dale W. A. Antibiotic prophylaxis in vascular surgery. Ann Surg. 1978 Sep;188(3):283–289. doi: 10.1097/00000658-197809000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kim C., Kwok Y. S., Saha S., Redberg R. F. Diagnosis of suspected coronary artery disease in women: a cost-effectiveness analysis. Am Heart J. 1999 Jun;137(6):1019–1027. doi: 10.1016/s0002-8703(99)70357-1. [DOI] [PubMed] [Google Scholar]
  15. L'Ecuyer P. B., Murphy D., Little J. R., Fraser V. J. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis. 1996 Mar;22(3):424–429. doi: 10.1093/clinids/22.3.424. [DOI] [PubMed] [Google Scholar]
  16. Lawrence L., Hall M. J. 1997 summary: National Hospital Discharge Survey. Adv Data. 1999 Aug 18;(308):1–16. [PubMed] [Google Scholar]
  17. Maki D. G., Bohn M. J., Stolz S. M., Kroncke G. M., Acher C. W., Myerowitz P. D. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thorac Cardiovasc Surg. 1992 Nov;104(5):1423–1434. [PubMed] [Google Scholar]
  18. Martin C. Antimicrobial prophylaxis in surgery: general concepts and clinical guidelines. French Study Group on Antimicrobial Prophylaxis in Surgery, French Society of Anesthesia and Intensive Care. Infect Control Hosp Epidemiol. 1994 Jul;15(7):463–471. doi: 10.1086/646952. [DOI] [PubMed] [Google Scholar]
  19. Martone W. J. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol. 1998 Aug;19(8):539–545. doi: 10.1086/647870. [DOI] [PubMed] [Google Scholar]
  20. Mossad S. B., Serkey J. M., Longworth D. L., Cosgrove D. M., 3rd, Gordon S. M. Coagulase-negative staphylococcal sternal wound infections after open heart operations. Ann Thorac Surg. 1997 Feb;63(2):395–401. doi: 10.1016/s0003-4975(96)00834-x. [DOI] [PubMed] [Google Scholar]
  21. Page C. P., Bohnen J. M., Fletcher J. R., McManus A. T., Solomkin J. S., Wittmann D. H. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg. 1993 Jan;128(1):79–88. doi: 10.1001/archsurg.1993.01420130087014. [DOI] [PubMed] [Google Scholar]
  22. Peduzzi P., Kamina A., Detre K. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol. 1998 Jun 15;81(12):1393–1399. doi: 10.1016/s0002-9149(98)00204-5. [DOI] [PubMed] [Google Scholar]
  23. Penketh A. R., Wansbrough-Jones M. H., Wright E., Imrie F., Pepper J. R., Parker D. J. Antibiotic prophylaxis for coronary artery bypass graft surgery. Lancet. 1985 Jun 29;1(8444):1500–1500. doi: 10.1016/s0140-6736(85)92267-6. [DOI] [PubMed] [Google Scholar]
  24. Platt R., Zaleznik D. F., Hopkins C. C., Dellinger E. P., Karchmer A. W., Bryan C. S., Burke J. F., Wikler M. A., Marino S. K., Holbrook K. F. Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. N Engl J Med. 1990 Jan 18;322(3):153–160. doi: 10.1056/NEJM199001183220303. [DOI] [PubMed] [Google Scholar]
  25. Platt R., Zucker J. R., Zaleznik D. F., Hopkins C. C., Dellinger E. P., Karchmer A. W., Bryan C. S., Burke J. F., Wikler M. A., Marino S. K. Prophylaxis against wound infection following herniorrhaphy or breast surgery. J Infect Dis. 1992 Sep;166(3):556–560. doi: 10.1093/infdis/166.3.556. [DOI] [PubMed] [Google Scholar]
  26. Smith T. L., Pearson M. L., Wilcox K. R., Cruz C., Lancaster M. V., Robinson-Dunn B., Tenover F. C., Zervos M. J., Band J. D., White E. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999 Feb 18;340(7):493–501. doi: 10.1056/NEJM199902183400701. [DOI] [PubMed] [Google Scholar]
  27. Suter F., Avai A., Fusco U., Gerundini M., Caprioli S., Maggiolo F. Teicoplanin versus cefamandole in the prevention of infection in total hip replacement. Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):793–796. doi: 10.1007/BF02111338. [DOI] [PubMed] [Google Scholar]
  28. VandenBergh M. F., Kluytmans J. A., van Hout B. A., Maat A. P., Seerden R. J., McDonnel J., Verbrugh H. A. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol. 1996 Dec;17(12):786–792. doi: 10.1086/647237. [DOI] [PubMed] [Google Scholar]
  29. Vuorisalo S., Pokela R., Syrjälä H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol. 1998 Apr;19(4):234–239. doi: 10.1086/647801. [DOI] [PubMed] [Google Scholar]
  30. Waldvogel F. A. New resistance in Staphylococcus aureus. N Engl J Med. 1999 Feb 18;340(7):556–557. doi: 10.1056/NEJM199902183400709. [DOI] [PubMed] [Google Scholar]
  31. Woods R. K., Dellinger E. P. Current guidelines for antibiotic prophylaxis of surgical wounds. Am Fam Physician. 1998 Jun;57(11):2731–2740. [PubMed] [Google Scholar]
  32. Zoutman D., McDonald S., Vethanayagan D. Total and attributable costs of surgical-wound infections at a Canadian tertiary-care center. Infect Control Hosp Epidemiol. 1998 Apr;19(4):254–259. doi: 10.1086/647804. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES